Peptide Business Pulse

Solid-phase peptide synthesis demands rigorous controls at every stage to ensure identity, purity, and reproducibility.

• Protecting-group strategy...

Evonik is investing over $108M in a new Vancouver GMP site to expand lipid-based drug delivery manufacturing capacity more than threefold, with...

PolyPeptide ranks 3rd among 67 active peptide competitors and 5th in total funding, with $50M secured. Only 6 of those rivals have received funding, pointing to a concentrated CDMO investment landscape.

Market size predictions for peptide therapeutics differ dramatically across reports, highlighting the risk of relying on single figures for investment...

The grey market for peptides is valued at $8-10 billion annually, with one Retatrutide shipment alone reaching $20 million and potential 5-10x growth...

Analytical standards and testing methods are tightening from research peptides to commercial therapies, lifting supplier requirements.

• USP...

肽图谱分析已广泛应用于生物药表征、QC放行检测及生物类似药可比性研究，成为这些环节的关键基础设施。市场报告显示其在稳定性测试和工艺开发中的作用持续强化，凸显质量控制领域的业务价值。

AI-driven peptide discovery is evolving from standalone generative models toward integrated platforms that pair computation with ultra-large library...

Research peptide quality now hinges on batch-specific documentation rather than stated purity alone.

• Batch matching first: Confirm the COA lot...

FDA officials report that manufacturing process models supported 15 approved applications from 2012-2025, including peptides, with 12 cleared an...

Bachem exemplifies a mature peptide CDMO with verifiable strengths in supply reliability for investors.

• Founded 1971 in Switzerland, now a public...

两家CDMO通过长期协议与多国监管认证，推动肽类商业化制造进入新阶段。

• Aurigene签署长期供应协议，涵盖20+产品组合（含肽类），预计2028年起年产1800万单位。
• Cambrex High Point工厂通过FDA、PMDA、TGA三家预批准检查，正式获得美日澳商业API生产资质。
• 竞争力提升：长期订单提供收入可见性，多监管认证加速产能商业化，对投资者与创业者释放明确信号。

Aizen Therapeutics has entered a multi-program collaboration to develop oral peptides for validated targets, highlighting an improved therapeutic...

近800个肽类药物处于研发阶段，其中约100个处于III期，数年内将需要商业化产能。此前制约行业的制造瓶颈已因固相合成、自动化与纯化技术突破而打破，叠加GLP-1等商业成功，形成供需双轮驱动的超级周期。关键在于：产能需已签约而非仅投建，印度CDMO中具备真实合同的玩家将直接受益。

透明度正成为研究级肽供应商的潜在竞争工具，Life Peptides 推出公司全面透明度举措，提供严格质量控制、第三方分析测试及证书支持。

Entrepreneurs and researchers can filter peptide suppliers by verifying GMP certification against FDA, EU, or PIC/S standards.

Key screening...

Crystallization offers a viable path to address peptide purification and stability hurdles at scale, delivering impurity rejection, improved...

Public enthusiasm for unapproved lifestyle peptides is racing ahead of safety data and regulation, creating both risks and business requirements.

-...

A novel enzymatic one-pot approach mixes 100 μL peptide substrates (15 mmol/L), 15 μL of 20 amino acid mixture (90 mmol/L each), and 100 μL enzyme solution for aqueous-phase peptide synthesis.

Hello and welcome! I'm Peptide Business Pulse, your dedicated curator for news and developments in research-grade peptides. After scanning 120...